Mevrometostat Update: Phase 2 Clinical Trial Keeps Showing Promising Results
/in Clinical Trial, Metastatic, Phase 2/by MaxCOMRADE Phase 2 Trial Initial Results: Combination of Olaparib and Radium-223 Shows Promise in Extending Progression-Free Survival
/in Clinical Trial, Metastatic, Phase 2/by MaxTALAPRO-2 Trial: Final OS Analisys Confirms Talazoparib + Enzalutamide Effectiveness in mCRPC
/in Clinical Trial, Metastatic, Phase 3/by MaxPT-112: FDA Clears Phase 3 Trial of Novel Therapy for Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxPembrolizumab Plus Enzalutamide Therapy Shows No Benefit in Metastatic Castration-Resistant Prostate Cancer Trial
/in Clinical Trial, Metastatic, Phase 3/by MaxSetback in Prostate Cancer Trial: CAPItello-280 Study for Truqap Discontinued
/in Clinical Trial, Metastatic, Phase 3/by MaxPhase 1 Trial: APG-5918 an EED Inhibitor for Prostate Cancer Therapy
/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Dual-Targeting PSMA And FRα Drug Conjugate Advances to U.S. Trial for Prostate Cancer June 18, 2026
- Phase 1 RIALTO Trial: Radiotherapy for Metastatic Prostate Cancer With Incomplete Hormone Response June 18, 2026
- Decipher Genomic Classifier Identifies Patients Who Benefit from Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer June 18, 2026
- CRISPR Advances June 16, 2026